PitchSend

Investor Presentaiton

CSL Behring Revenue up 14%¹ Therapy Revenue $m Change % lg 2,757 23% Albumin 613 8% Haemophilia 662 8% Specialty 976 6% Other² Total • Performance Strong growth across all geographies PRIVIGENⓇ/INTRAGAM® +27%, HIZENTRA +18% Significant patient demand in core indications HIZENTRAⓇ 50ml pre-filled syringe launch in the US Strong growth in emerging markets Solid growth in US and EU Competition remains strong in China IDELVIONⓇ remains the standard of care, +7% Market leader in key markets Significant HCP and patient interest in HEMGENIXⓇ KCENTRAⓇ +12% Continues to be the gold standard for warfarin reversal HAEGARDA® +9% Strong EU performance Continue to add new patients Hizentra Immune Globulin Subcutaneous (Human) 20% Liquid HUMATE-P Antihemophilic Factor/von Willebrand Factor Complex (Human) KCENTRAⓇ Prothrombin Complex Concentrate (Human) Major Brands AlbuRxⓇ Haemate P 1000 HEMGENIX® etranacogene dezaparvovec-drib Urgent Warfarin Reversal HAEMOCOMPLETAN P Fibrinogen Concentrate privigen Immune Globulin Intravenous (Human), 10% Liquid IDELVION Coagulation Factor IX (Recombinant, Albumin Fusion Protein HAEGARDA C1 Esterase Inhibitor Subcutaneous (Human) BERINERT C1 Esterase Inhibitor, Human 230 (16%) COVID-19 vaccine supply contract in prior period 5,238 14% 1. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail. 2. Includes HPV royalties & Hyperimmunes 5 Driven by Our Promise CSL

View entire presentation